TORONTO, May 17, 2018 (Newswire.com) - Live webinar May 31, 2018
In December 2016 the US Congress enacted the 21st Century Cures Act, which required the FDA to facilitate an efficient development program for, and expedite the review of, new medicines meeting the definition of a regenerative advanced therapy (RAT) (Section 3033). The RAT designation in the legislation is now referred to as the Regenerative Medicine Advanced Therapy (RMAT) designation.
Now that the first two of these therapies have been approved, the supply chain of patient- and donor-derived regenerative medicine products will fall under increasing pressure for standardization and increased regulatory requirements. Much of the early regulatory focus has been on material processing with four guidance documents issued in a regulatory framework established by the FDA on November 16, 2017, its focus is on recovery, isolation, and delivery. Cryoport believes that enhanced traceability within the logistics distribution will also be subjected to additional regulatory requirements due to the fragile aspect of the drug product and the disproportionate risk of improper cold chain management on the viability of the therapies.
- Traceability within cold chain logistics for precision medicine falls into the following need areas:
- Traceability of the identity of the therapy (i.e., chain of identity)
- Traceability of the distribution of the therapy (i.e., chain of custody)
- Traceability of the environmental control of the therapy (i.e., chain of condition)
- Traceability of the equipment used in managing the environmental control of the therapy (i.e., chain of compliance)
The first three elements identified are already well established within the industry; however, they will need to be enhanced and integrated into a single data stream for cross-referencing and accountability. However, the fourth element, a chain of compliance, is not currently required but is necessary when considering risk management in personalized therapy distribution. Chain of compliance includes tracking and understanding courier performance, equipment validation, requalification, performance, sterility controls and cleaning processes. In addition, it includes the ability to manage the packaging utilized in product distribution in a manner similar to manufacturing equipment traceability within a manufacturing environment.
Join Mark W. Sawicki, Ph.D., Chief Commercial Officer for Cryoport as he covers and discusses these elements in a live session on Thursday, May 31, 2018, at 11 a.m. EDT (4 p.m. BST/UK).
For more information or complimentary registration visit: Cold Chain Logistics for Precision Medicine: Anticipating Future Regulatory Requirements.
Xtalks, powered by Honeycomb Worldwide Inc., is a leading provider of educational webinars to the global life science, food, and medical device community. Every year thousands of industry practitioners (from life science, food, and medical device companies, private & academic research institutions, healthcare centers, etc.) turn to Xtalks for access to quality content. Xtalks helps Life Science professionals stay current with industry developments, trends, and regulations. Xtalks webinars also provide perspectives on key issues from top industry thought leaders and service providers.
To learn more about Xtalks visit http://xtalks.com
For information about hosting a webinar visit http://xtalks.com/why-host-a-webinar.
Tel: +1 (416) 977-6555 ext 352